CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) - 9 months ended Jul. 31, 2018 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total Shareholders Equity [Member]	Noncontrolling Interest [Member]	Total
Balance, October 31, 2017 at Oct. 31, 2017	$ 166,028	$ 163,931,079	$ (156,174,184)	$ 7,922,923		$ 7,922,923
Balance, October 31, 2017 (in Shares) at Oct. 31, 2017	16,602,759
Stock option compensation to employees and directors		3,598,986		3,598,986		3,598,986
Stock option compensation to consultants		197,040		197,040		197,040
Common stock issued upon exercise of stock options	$ 398	(398)
Common stock issued upon exercise of stock options (in Shares)	39,816
Common stock award issued to employee pursuant to stock incentive plan	$ 15,000	1,358,940		1,373,940		1,373,940
Common stock award issued to employee pursuant to stock incentive plan (in Shares)	1,500,000
Warrants issued to consultant		57,050		57,050		57,050
Common stock issued to consultants	$ 53	14,949		15,002		15,002
Common stock issued to consultants (in Shares)	5,347
Common stock issued in at-the-market offering	$ 5,482	1,780,547		1,786,029		1,786,029
Common stock issued in at-the-market offering (in Shares)	548,224
Issuance of noncontrolling interest in Certainty Therapeutics, Inc		68,974		68,974	$ (4,318)	64,656
Net loss			(8,693,532)	(8,693,532)	(158,032)	(8,851,564)
Balance, July 31, 2018 at Jul. 31, 2018	$ 186,961	$ 171,007,167	$ (164,867,716)	$ 6,326,412	$ (162,350)	$ 6,164,062
Balance, July 31, 2018 (in Shares) at Jul. 31, 2018	18,696,146